Altamira Therapeutics Ltd (CYTOF)
Altamira Therapeutics Ltd. is a common stock listing of a healthcare company focused on preclinical-stage biopharmaceutical research and development. The company works in Switzerland, Australia, the United States, and Europe, and is based in Hamilton, Bermuda. Its programs include peptide-based nanoparticle technology for RNA delivery to extrahepatic tissues through the xPhore platform, as well as Bentrio, a drug-free nasal spray designed for protection against airborne viruses and allergens. Altamira is also advancing AM-401 for KRAS-driven cancer, AM-411 for rheumatoid arthritis, and AM-125, which has reached the post-phase II stage for intranasal treatment of vertigo. The company was previously known as Auris Medical Holding Ltd. and adopted its current name in July 2021.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CYTO.F
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 28, 2026
|
-0.1x
|
0.1x
|
—
|
435.478 K
|
1.341 M
|
58.8%
|
—
|
-21.0
|
—
|
77.8%
|
